<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699293</url>
  </required_header>
  <id_info>
    <org_study_id>17-2915</org_study_id>
    <nct_id>NCT03699293</nct_id>
  </id_info>
  <brief_title>NSAIDs vs. Coxibs in the Presence of Aspirin</brief_title>
  <official_title>NSAIDs vs. Coxibs in the Presence of Aspirin: Effects on Platelet Function, Endothelial Function, and Biomarkers of Inflammation in Subjects With Rheumatoid Arthritis and Increased Cardiovascular Risk or Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inova Health Care Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inova Health Care Services</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this single site, randomized, crossover study is to evaluate the&#xD;
      pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet&#xD;
      function, biomarkers of inflammation and endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The relative cardiovascular safety of NSAIDs, particularly among patients with cardiovascular&#xD;
      disease (CVD) or at higher CVD risk, has generated considerable concern among both patients&#xD;
      and physicians because of knowledge gaps in the evidence relative to comparative safety and&#xD;
      pharmacodynamic interactions between aspirin and NSAIDs. In the recently reported PRECISION&#xD;
      trial, a moderate dose of celecoxib was found to be noninferior to ibuprofen or naproxen with&#xD;
      respect to cardiovascular safety in patients with arthritis at increased CVD risk. At this&#xD;
      time, no comparative prior data are available analyzing the effects of NSAIDs vs. Coxibs in&#xD;
      the presence of aspirin on platelet function, biomarkers of inflammation and endothelial&#xD;
      function.&#xD;
&#xD;
      Thirty patients with rheumatoid arthritis who are at high cardiovascular (CV) risk or with&#xD;
      established CV disease will be enrolled in the study. Patients taking anticoagulant therapy&#xD;
      or any other antiplatelet agent other than aspirin will be excluded.&#xD;
&#xD;
      Patients will be treated with immediate release 81mg aspirin for 4 weeks in the run-in period&#xD;
      followed by randomization to celecoxib (200 mg bid) vs. naproxen sodium (550 mg bid) for 4&#xD;
      weeks and then cross over to the other drug for another 4 weeks. Blood and urine samples will&#xD;
      be collected at baseline before the aspirin run in period, 24±4 hr after the last dose of&#xD;
      aspirin in the run in period, 24±4 hr after the last dose of the first period study drug and&#xD;
      24±4 hr after the last dose of the second period study drug. Assays for platelet function,&#xD;
      biomarkers of inflammation and endothelial function will be performed at these time points.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 22, 2018</start_date>
  <completion_date type="Anticipated">November 24, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 24, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Qualified patients will be treated with immediate release 81mg aspirin for 4 weeks in the run-in period followed by randomization to celecoxib (200 mg bid) vs. naproxen sodium (550 mg bid) for 4 weeks and then cross over to the other drug for another 4 weeks. Blood and urine samples will be collected before the aspirin run-in period (baseline), 24±4 hrs after the last dose of aspirin in the run-in period, 24±4 hr after the last dose of the study drug in the first period and 24±4 hr after the last dose of the study drug in the second period. Assays for platelet function, biomarkers of inflammation and endothelial function will be performed at these time points</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in platelet aggregation by light transmittance aggregometry between treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum TxB2</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in serum TxB2 between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine thromboxane</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in urine thromboxane between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine 8 iso prostaglandin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in urine 8 iso prostaglandin between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function by EndoPAT</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in endothelial function by EndoPAT (Endothelial Peripheral Arterial Tone) between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble markers of circulating adhesion molecules (VCAM, ICAM).</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in soluble markers of circulating adhesion molecules (VCAM, and ICAM) between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hsCRP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in hsCRP between treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in Oxidized LDL between treatment groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>ASA and Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA and Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib 200mg capsule</intervention_name>
    <description>celecoxib 200mg twice a day for 4 weeks</description>
    <arm_group_label>ASA and Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naproxen sodium 550mg tablet</intervention_name>
    <description>naproxen sodium 550mg twice a day for 4 weeks</description>
    <arm_group_label>ASA and Naproxen</arm_group_label>
    <other_name>Aleve</other_name>
    <other_name>Naprosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 81mg tablet</intervention_name>
    <description>81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period</description>
    <arm_group_label>ASA and Celecoxib</arm_group_label>
    <arm_group_label>ASA and Naproxen</arm_group_label>
    <other_name>Bayer Aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Qualified patients should have all 4 main criteria&#xD;
&#xD;
          1. Age 18-75 years of age for patients who regularly use NSAIDs.&#xD;
&#xD;
          2. Age 18-65 years of age for patients who do not regularly use NSAIDs&#xD;
&#xD;
          3. Able to give informed consent&#xD;
&#xD;
          4. Subjects with CVD or increased CV risk. Please see definitions for each criteria&#xD;
             below:&#xD;
&#xD;
               -  Increased CV risk (Subjects should have at least 3 of the following)&#xD;
&#xD;
                    -  &gt; 55 years of age&#xD;
&#xD;
                    -  Hypertension&#xD;
&#xD;
                    -  Dyslipidemia (LDL &gt; 160 mg/dL or HDL &lt; 40 mg/dL in females and &lt; 35 mg/dL in&#xD;
                       males or subjects currently receiving lipid lowering therapy as standard of&#xD;
                       care (i.e. statin drugs, prescription ω 3-acid ethyl esters, fibrates or&#xD;
                       prescription niacin [≥1,000 mg/d])&#xD;
&#xD;
                    -  Family history of premature CV disease (MI, angina pectoris, heart failure,&#xD;
                       cardiac death or coronary revascularization, stroke, carotid endarterectomy,&#xD;
                       or other arterial surgery or angioplasty for atherosclerotic vascular&#xD;
                       disease in a parent, grandparent, or sibling with symptom onset or diagnosis&#xD;
                       before age 55 y for males and 65 y for females)&#xD;
&#xD;
                    -  Current smoker&#xD;
&#xD;
                    -  Left ventricular hypertrophy&#xD;
&#xD;
                    -  Documented ankle brachial index of &lt;0.9&#xD;
&#xD;
                    -  History of microalbuminuria, urine protein-creatinine ratio of &gt;2&#xD;
&#xD;
               -  CV disease (defined as one of the following):&#xD;
&#xD;
                    -  Calcium score of &gt;0&#xD;
&#xD;
                    -  ≥ 50 % occlusion of a coronary artery by angiography&#xD;
&#xD;
                    -  ≥ 50 % occlusion of a carotid artery by angiography or ultrasound&#xD;
&#xD;
                    -  History of stable angina&#xD;
&#xD;
                    -  Symptomatic peripheral arterial disease&#xD;
&#xD;
                    -  Prior MI, unstable angina, percutaneous coronary intervention, CABG, TIA,&#xD;
                       ischemic stroke, carotid endarterectomy, or other arterial surgery or&#xD;
                       angioplasty, which have occurred &gt; 3 months prior to screening visit&#xD;
&#xD;
                    -  Diabetes Mellitus type 1 or 2 (considered a CV disease equivalent).&#xD;
&#xD;
               -  Clinical diagnosis of rheumatoid arthritis, as determined by individual patient&#xD;
                  and physician, requiring daily treatment with NSAIDs.&#xD;
&#xD;
        Exclusion Criteria: Subjects with any of the following criteria will be excluded from this&#xD;
        study:&#xD;
&#xD;
          1. Unstable angina, MI, CVA, CABG &lt;3 months from screening visit&#xD;
&#xD;
          2. Planned coronary, cerebrovascular, or peripheral revascularization&#xD;
&#xD;
          3. Undergone major surgery within 3 months prior to screening visit or has planned major&#xD;
             surgery during the study period&#xD;
&#xD;
          4. Uncontrolled hypertension (SBP &gt;190, DBP &gt;100 mm Hg) during screening visit&#xD;
&#xD;
          5. Uncontrolled arrhythmia &lt; 3 months from screening visit&#xD;
&#xD;
          6. NYHA class III-IV heart failure or if available, ejection fraction ≤ 35 %&#xD;
&#xD;
          7. Within 6 months prior to screening visit, a history of ACS or hospitalization for&#xD;
             heart failure&#xD;
&#xD;
          8. Oral corticosteroid, prednisone (or equivalent) &gt; 20 mg daily&#xD;
&#xD;
          9. Anticoagulation therapy&#xD;
&#xD;
         10. Antiplatelet therapy except for aspirin&#xD;
&#xD;
         11. GI ulceration &lt; 60 days before screening visit&#xD;
&#xD;
         12. GI bleeding, perforation, obstruction &lt; 6 months of screening visit&#xD;
&#xD;
         13. Inflammatory bowel disease, diverticulitis active &lt; 6 months of screening visit&#xD;
&#xD;
         14. AST, ALT, or BUN &gt;2x the upper limit normal (within 30 days prior to screening visit)&#xD;
&#xD;
         15. Creatinine level &gt;1.7 mg/dL in men, 1.5 mg/dL in women (within 30 days prior to&#xD;
             screening visit)&#xD;
&#xD;
         16. On fluconazole, methotrexate, or lithium therapy&#xD;
&#xD;
         17. Malignancy &lt; 5 years before screening visit&#xD;
&#xD;
         18. Other known, active, significant GI, hepatic, renal, or coagulation disorders&#xD;
&#xD;
         19. Allergy, allergic-type reactions or hypersensitivity (e.g. asthma, urticaria, etc.) to&#xD;
             any of the study medications and its components (i.e. sulfonamides)&#xD;
&#xD;
         20. History of any disease of condition that, in the opinion of the investigator would&#xD;
             place the subject at an unacceptable risk to participate in this study&#xD;
&#xD;
         21. Any clinically relevant abnormal findings in physical examination, vital signs, or&#xD;
             previous laboratory works that, in the opinion of the investigator, may compromise the&#xD;
             safety of the subject to participate&#xD;
&#xD;
         22. Subjects who are legally institutionalized&#xD;
&#xD;
         23. Lactating females or females of childbearing potential except for those who are&#xD;
             surgically sterile or postmenopausal-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Bliden, BS, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Inova Health Care Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Bliden, BS, MBA</last_name>
    <phone>(703) 776-7702</phone>
    <email>kevin.bliden@inova.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emiliya Bakalska, BA</last_name>
    <phone>(410) 367-2592</phone>
    <email>emiliya.bakalska@inova.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inova Heart and Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Fitzgerald, RN, MS</last_name>
      <phone>703-776-3330</phone>
      <email>andrea.fitzgerald@inova.org</email>
    </contact>
    <contact_backup>
      <last_name>Solomon Yeon, MS</last_name>
      <phone>(703) 776-4726</phone>
      <email>solomon.yeaon@inova.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>October 4, 2018</last_update_submitted>
  <last_update_submitted_qc>October 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to share IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

